Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
11.78
+0.15 (1.29%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Design Therapeutics Employees
Design Therapeutics had 54 employees as of March 31, 2026. The number of employees did not change since the number was last reported on December 31, 2025.
Employees
54
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,290,981
Market Cap
735.74M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 54 | 0 | - | 54 | 0 |
| Dec 31, 2025 | 54 | 0 | - | 54 | 0 |
| Dec 31, 2024 | 54 | -4 | -6.90% | 54 | 0 |
| Dec 31, 2023 | 58 | 0 | - | 58 | 0 |
| Dec 31, 2022 | 58 | 20 | 52.63% | 58 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Omeros | 175 |
| Solid Biosciences | 121 |
| BridgeBio Oncology Therapeutics | 106 |
| Aclaris Therapeutics | 73 |
| CytomX Therapeutics | 69 |
| Candel Therapeutics | 55 |
| Climb Bio | 29 |
| Faeth Therapeutics | 29 |
DSGN News
- 24 days ago - Design Therapeutics initiates patient dosing in DT-818 trial - TheFly
- 24 days ago - Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - GlobeNewsWire
- 7 weeks ago - Design Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Design Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Design Therapeutics Transcript: Status update - Transcripts
- 2 months ago - Design Therapeutics Press release: Status update - Filings
- 2 months ago - Design Therapeutics Slides: Status update - Filings